MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

TLRY

6.95

+0.43%↑

Home・Akcijų sąrašas・Fate Therapeutics Inc

Fate Therapeutics Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

1.29 -3.73

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.25

Max

1.35

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-124K -32M
Pardavimai	-372K 1.4M
Pelnas, tenkantis vienai akcijai	-0.27
Pelno marža	-2,364.792
Darbuotojai	161
EBITDA	-13M -42M

Rekomendacijos
By TipRanks
Rekomendacijos	Neutralu
12 mėnesių prognozė	+52.67% upside

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-36M 138M
Ankstesnė atidarymo kaina	5.02
Ankstesnė uždarymo kaina	1.29

Naujienos nuotaikos

By Acuity

15%

85%

22 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

0.9101 / 1.14 Palaikymas ir pasipriešinimas

Fate Therapeutics Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-14 23:36; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

2026-04-14 23:24; UTC

Karštos akcijos

Stocks to Watch: Gloo, Broadcom, GitLab

2026-04-14 22:42; UTC

Įsigijimai, susijungimai, perėmimai

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

2026-04-14 21:32; UTC

Pagrindinės rinkos jėgos

GitLab Shares Rise on Expanded Google Cloud Collaboration

2026-04-14 23:54; UTC

Rinkos pokalbiai

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

2026-04-14 23:34; UTC

Rinkos pokalbiai

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026-04-14 22:54; UTC

Uždarbis

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

2026-04-14 22:54; UTC

Uždarbis

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Targets Deal Completion Toward End of 3Q

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

2026-04-14 22:17; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

2026-04-14 22:16; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

2026-04-14 22:15; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

2026-04-14 22:14; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

2026-04-14 22:13; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

2026-04-14 22:12; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

2026-04-14 22:10; UTC

Įsigijimai, susijungimai, perėmimai

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

2026-04-14 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Basic Materials Roundup: Market Talk

2026-04-14 20:33; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 20:32; UTC

Karštos akcijos

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

2026-04-14 19:59; UTC

Įsigijimai, susijungimai, perėmimai

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026-04-14 19:38; UTC

Uždarbis

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026-04-14 19:27; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2026-04-14 19:21; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026-04-14 19:09; UTC

Įsigijimai, susijungimai, perėmimai

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

2026-04-14 18:30; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-04-14 18:30; UTC

Rinkos pokalbiai

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Akcijų palyginimas

Kainos pokytis

Fate Therapeutics Inc Prognozė

Kainos tikslas

By TipRanks

52.67% į viršų

12 mėnesių prognozė

Vidutinis 2 USD 52.67%

Aukščiausias 2 USD

Žemiausias 2 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Fate Therapeutics Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

3 ratings

Pirkti

Laikyti

Parduoti

Remiantis 3 analitikų, pateikusių Fate Therapeutics Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

0.9101 / 1.14Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Rinkos nuotaikos

By Acuity

22 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Apie bendrovę Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.